Open access
Oct 2026
Firstline treatment with ruxolitinib versus best available therapy in patients with polycythemia vera: results from the randomized RuxoBEAT trial
It is suggested that RUX may induce clinically meaningful additional disease improvements in first-line therapy of PV patients with polycythemia vera in the randomized multicenter RuxoBEAT clinical trial.
Steffen Koschmieder, S. Isfort, Lino L. Teichmann et al.
· Blood Cancer Journal · 0 citations